$SLNO
SOLENO THERAPEUTICS INC

2024 Q4 Form 10-Q Financial Statement

#000095017024122276 Filed on November 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $49.20M
YoY Change 1381.84%
% of Gross Profit
Research & Development $30.14M
YoY Change 398.73%
% of Gross Profit
Depreciation & Amortization $500.0K
YoY Change 2.04%
% of Gross Profit
Operating Expenses $80.21M
YoY Change 672.61%
Operating Profit -$80.21M
YoY Change 672.61%
Interest Expense $3.596M
YoY Change 2015.29%
% of Operating Profit
Other Income/Expense, Net $3.596M
YoY Change -850.73%
Pretax Income -$76.62M
YoY Change 605.49%
Income Tax
% Of Pretax Income
Net Earnings -$76.62M
YoY Change 605.42%
Net Earnings / Revenue
Basic Earnings Per Share -$1.83
Diluted Earnings Per Share -$1.83
COMMON SHARES
Basic Shares Outstanding 43.12M 38.87M
Diluted Shares Outstanding 41.88M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $256.8M
YoY Change 389.66%
Cash & Equivalents $48.40M
Short-Term Investments $208.4M
Other Short-Term Assets $1.423M
YoY Change 16.64%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $258.2M
YoY Change 381.18%
LONG-TERM ASSETS
Property, Plant & Equipment $196.0K
YoY Change 1206.67%
Goodwill
YoY Change
Intangibles $7.291M
YoY Change -21.05%
Long-Term Investments $27.95M
YoY Change
Other Assets $83.00K
YoY Change -49.7%
Total Long-Term Assets $38.51M
YoY Change 289.39%
TOTAL ASSETS
Total Short-Term Assets $258.2M
Total Long-Term Assets $38.51M
Total Assets $296.7M
YoY Change 366.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.243M
YoY Change 94.12%
Accrued Expenses $5.618M
YoY Change 12.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.96M
YoY Change -48.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $17.05M
YoY Change 50.31%
Total Long-Term Liabilities $17.05M
YoY Change 50.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.96M
Total Long-Term Liabilities $17.05M
Total Liabilities $32.01M
YoY Change -20.63%
SHAREHOLDERS EQUITY
Retained Earnings -$396.3M
YoY Change 49.49%
Common Stock $660.1M
YoY Change 128.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $264.7M
YoY Change
Total Liabilities & Shareholders Equity $296.7M
YoY Change 366.9%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$76.62M
YoY Change 605.42%
Depreciation, Depletion And Amortization $500.0K
YoY Change 2.04%
Cash From Operating Activities -$14.93M
YoY Change 135.43%
INVESTING ACTIVITIES
Capital Expenditures $191.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $4.231M
YoY Change
Cash From Investing Activities $4.040M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.275M
YoY Change -94.23%
NET CHANGE
Cash From Operating Activities -14.93M
Cash From Investing Activities 4.040M
Cash From Financing Activities 2.275M
Net Change In Cash -8.611M
YoY Change -126.05%
FREE CASH FLOW
Cash From Operating Activities -$14.93M
Capital Expenditures $191.0K
Free Cash Flow -$15.12M
YoY Change 138.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001484565
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
SOLENO THERAPEUTICS INC
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
slno Unpaid Costs For Issuing Common Stock And Pre Funded Warrants
UnpaidCostsForIssuingCommonStockAndPreFundedWarrants
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityCurrent
CY2024Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36593
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0523891
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Marine Parkway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
213-8444
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
SLNO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43117432
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48413000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
169681000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
208363000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1423000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1677000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
258199000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
171358000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
196000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2992000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
407000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7291000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8749000
CY2024Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
27945000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
83000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
165000
CY2024Q3 us-gaap Assets
Assets
296706000
CY2023Q4 us-gaap Assets
Assets
180691000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6243000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3149000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3408000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3135000
CY2024Q3 slno Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1762000
CY2023Q4 slno Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
3393000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
448000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
273000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3101000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1555000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14962000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11505000
CY2024Q3 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
14464000
CY2023Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
11549000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2581000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
130000
CY2024Q3 us-gaap Liabilities
Liabilities
32007000
CY2023Q4 us-gaap Liabilities
Liabilities
23184000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41041216
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41041216
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31678159
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31678159
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
41000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
32000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
660041000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
433885000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
895000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396278000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-276410000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
264699000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
157507000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
296706000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
180691000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30138000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6043000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57082000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16500000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
49197000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3318000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
68558000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9341000
CY2024Q3 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
877000
CY2023Q3 slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
1021000
slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
2915000
slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
1633000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
80212000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
10382000
us-gaap Operating Expenses
OperatingExpenses
128555000
us-gaap Operating Expenses
OperatingExpenses
27474000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-80212000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10382000
us-gaap Operating Income Loss
OperatingIncomeLoss
-128555000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27474000
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
653000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
652000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3596000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
174000
us-gaap Investment Income Interest
InvestmentIncomeInterest
8687000
us-gaap Investment Income Interest
InvestmentIncomeInterest
434000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3596000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-479000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8687000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-218000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-76616000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10861000
us-gaap Net Income Loss
NetIncomeLoss
-119868000
us-gaap Net Income Loss
NetIncomeLoss
-27692000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1049000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
898000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-75568000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10862000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-118973000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27693000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.83
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.83
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.95
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.65
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41879025
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41879025
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11436748
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11436748
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38917169
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38917169
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10443186
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10443186
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
157507000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6445000
CY2024Q1 slno Stock Issued During Period Value Exercise Of Common Stock Warrants And Pre Funded Common Stock Warrants
StockIssuedDuringPeriodValueExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrants
923000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-15000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-105000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-21398000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
143386000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7160000
CY2024Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
9746000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
148955000
CY2024Q2 slno Stock Issued During Period Value Exercise Of Common Stock Warrants And Pre Funded Common Stock Warrants
StockIssuedDuringPeriodValueExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrants
2620000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-537000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-46000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21854000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
280757000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
56598000
CY2024Q3 slno Issuance Of Restricted Stock Units Value And Option Exercises Under Equity Incentive Plan
IssuanceOfRestrictedStockUnitsValueAndOptionExercisesUnderEquityIncentivePlan
1000
CY2024Q3 slno Stock Issued During Period Value Exercise Of Common Stock Warrants And Pre Funded Common Stock Warrants
StockIssuedDuringPeriodValueExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrants
2147000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-764000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1049000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-76616000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
264699000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10348000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
495000
CY2023Q1 slno Issuance Of Restricted Stock Units Value And Option Exercises Under Equity Incentive Plan
IssuanceOfRestrictedStockUnitsValueAndOptionExercisesUnderEquityIncentivePlan
136000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
16000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-8356000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2639000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1204000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
9973000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7101000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-16000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8475000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
12426000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2201000
CY2023Q3 slno Class Of Warrant Or Right Exercised Value
ClassOfWarrantOrRightExercisedValue
19445000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-10000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10861000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
23220000
us-gaap Profit Loss
ProfitLoss
-119868000
us-gaap Profit Loss
ProfitLoss
-27692000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1484000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1469000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3495000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
slno Noncash Lease Expense
NoncashLeaseExpense
250000
slno Noncash Lease Expense
NoncashLeaseExpense
254000
us-gaap Share Based Compensation
ShareBasedCompensation
70203000
us-gaap Share Based Compensation
ShareBasedCompensation
4036000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
652000
slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
2915000
slno Asset Acquisition Contingent Consideration Change In Fair Value
AssetAcquisitionContingentConsiderationChangeInFairValue
1633000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-3000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-1000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-279000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
177000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3094000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1338000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
273000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-177000
slno Increase Decrease In Accrued Clinical Trial Site Costs
IncreaseDecreaseInAccruedClinicalTrialSiteCosts
-1631000
slno Increase Decrease In Accrued Clinical Trial Site Costs
IncreaseDecreaseInAccruedClinicalTrialSiteCosts
15000
slno Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-152000
slno Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-242000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1546000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
266000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45105000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18626000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
210000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
308915000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
77000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-232125000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
148955000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
slno Proceeds From Sale Of Common Stock And Common Stock Warrants Net Of Issuance Costs
ProceedsFromSaleOfCommonStockAndCommonStockWarrantsNetOfIssuanceCosts
0
slno Proceeds From Sale Of Common Stock And Common Stock Warrants Net Of Issuance Costs
ProceedsFromSaleOfCommonStockAndCommonStockWarrantsNetOfIssuanceCosts
17074000
slno Proceeds From Exercise Of Common Stock Warrants And Pre Funded Common Stock Warrants Net Of Costs
ProceedsFromExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrantsNetOfCosts
5690000
slno Proceeds From Exercise Of Common Stock Warrants And Pre Funded Common Stock Warrants Net Of Costs
ProceedsFromExerciseOfCommonStockWarrantsAndPreFundedCommonStockWarrantsNetOfCosts
19445000
slno Proceeds Received Prior To For Issuance Of Common Stock And Pre Funded Warrants
ProceedsReceivedPriorToForIssuanceOfCommonStockAndPreFundedWarrants
0
slno Proceeds Received Prior To For Issuance Of Common Stock And Pre Funded Warrants
ProceedsReceivedPriorToForIssuanceOfCommonStockAndPreFundedWarrants
19932000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1317000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
155962000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56461000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-121268000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
37835000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
169681000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14602000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48413000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52437000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
597000
slno Unpaid Costs For Issuing Common Stock And Pre Funded Warrants
UnpaidCostsForIssuingCommonStockAndPreFundedWarrants
199000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45100000
us-gaap Net Income Loss
NetIncomeLoss
-119900000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396300000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48400000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
208400000
CY2024Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
27900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, the valuation of financial instruments, stock-based compensation, accrued costs for services rendered in connection with third-party contractor clinical trial activities, and the valuation of contingent liabilities for the purchase price of assets obtained through acquisition.</span></p>
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
235410000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
903000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
236308000
slno Milestones Payment
MilestonesPayment
100000000
CY2023 slno Milestones Payment
MilestonesPayment
200000000
slno Percentage Of Probability Of Achieving Milestone
PercentageOfProbabilityOfAchievingMilestone
0.88
CY2023 slno Percentage Of Probability Of Achieving Milestone
PercentageOfProbabilityOfAchievingMilestone
0.88
CY2024Q3 slno Operating Lease Right Of Use Asset Increase
OperatingLeaseRightOfUseAssetIncrease
2800000
CY2024Q3 slno Increase In Operating Lease Liability
IncreaseInOperatingLeaseLiability
2800000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
400000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
300000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2600000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100000
slno Lessee Operating Lease Extension Expiration Month And Year
LesseeOperatingLeaseExtensionExpirationMonthAndYear
2025-05
CY2023 slno Operating Lease Right Of Use Asset Increase
OperatingLeaseRightOfUseAssetIncrease
600000
CY2023 slno Increase In Operating Lease Liability
IncreaseInOperatingLeaseLiability
600000
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P17M
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
137000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
76000
us-gaap Operating Lease Cost
OperatingLeaseCost
291000
us-gaap Operating Lease Cost
OperatingLeaseCost
235000
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
4000
us-gaap Variable Lease Cost
VariableLeaseCost
12000
CY2024Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
54000
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
12000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
147000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
33000
CY2024Q3 us-gaap Lease Cost
LeaseCost
195000
CY2023Q3 us-gaap Lease Cost
LeaseCost
88000
us-gaap Lease Cost
LeaseCost
450000
us-gaap Lease Cost
LeaseCost
268000
us-gaap Operating Lease Payments
OperatingLeasePayments
248000
us-gaap Operating Lease Payments
OperatingLeasePayments
264000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
64000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
526000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
751000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
861000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
942000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
665000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3809000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
780000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3029000
CY2024Q3 us-gaap Other Commitment
OtherCommitment
2800000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 slno Public Offering Price Per Pre Funded Warrant
PublicOfferingPricePerPreFundedWarrant
19.99
CY2023Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
129000000
CY2023Q4 slno Stock Issued Issuance Costs
StockIssuedIssuanceCosts
8200000
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8168565
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13071883
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56598000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2201000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
70203000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4036000
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.21
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
37.84
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.8
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41879025
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41879025
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11436748
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11436748
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38917169
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38917169
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10443186
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10443186
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10812067
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21765365
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-122276-index-headers.html Edgar Link pending
0000950170-24-122276-index.html Edgar Link pending
0000950170-24-122276.txt Edgar Link pending
0000950170-24-122276-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slno-20240930.htm Edgar Link pending
slno-20240930.xsd Edgar Link pending
slno-ex31_1.htm Edgar Link pending
slno-ex31_2.htm Edgar Link pending
slno-ex32_1.htm Edgar Link pending
slno-20240930_htm.xml Edgar Link completed
slno-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable